150 related articles for article (PubMed ID: 14656475)
1. Mullerian Inhibiting Substance induces NFkB signaling in breast and prostate cancer cells.
Hoshiya Y; Gupta V; Segev DL; Hoshiya M; Carey JL; Sasur LM; Tran TT; Ha TU; Maheswaran S
Mol Cell Endocrinol; 2003 Dec; 211(1-2):43-9. PubMed ID: 14656475
[TBL] [Abstract][Full Text] [Related]
2. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
[TBL] [Abstract][Full Text] [Related]
3. Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway.
Segev DL; Ha TU; Tran TT; Kenneally M; Harkin P; Jung M; MacLaughlin DT; Donahoe PK; Maheswaran S
J Biol Chem; 2000 Sep; 275(37):28371-9. PubMed ID: 10874041
[TBL] [Abstract][Full Text] [Related]
4. Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.
Segev DL; Hoshiya Y; Hoshiya M; Tran TT; Carey JL; Stephen AE; MacLaughlin DT; Donahoe PK; Maheswaran S
Proc Natl Acad Sci U S A; 2002 Jan; 99(1):239-44. PubMed ID: 11773638
[TBL] [Abstract][Full Text] [Related]
5. Mullerian-inhibiting substance induces Gro-beta expression in breast cancer cells through a nuclear factor-kappaB-dependent and Smad1-dependent mechanism.
Gupta V; Yeo G; Kawakubo H; Rangnekar V; Ramaswamy P; Hayashida T; MacLaughlin DT; Donahoe PK; Maheswaran S
Cancer Res; 2007 Mar; 67(6):2747-56. PubMed ID: 17363596
[TBL] [Abstract][Full Text] [Related]
6. The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling.
Visser JA; Olaso R; Verhoef-Post M; Kramer P; Themmen AP; Ingraham HA
Mol Endocrinol; 2001 Jun; 15(6):936-45. PubMed ID: 11376112
[TBL] [Abstract][Full Text] [Related]
7. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK
Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113
[TBL] [Abstract][Full Text] [Related]
8. Mullerian inhibiting substance regulates NFkappaB signaling and growth of mammary epithelial cells in vivo.
Segev DL; Hoshiya Y; Stephen AE; Hoshiya M; Tran TT; MacLaughlin DT; Donahoe PK; Maheswaran S
J Biol Chem; 2001 Jul; 276(29):26799-806. PubMed ID: 11356848
[TBL] [Abstract][Full Text] [Related]
9. Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor.
Gouédard L; Chen YG; Thevenet L; Racine C; Borie S; Lamarre I; Josso N; Massague J; di Clemente N
J Biol Chem; 2000 Sep; 275(36):27973-8. PubMed ID: 10854429
[TBL] [Abstract][Full Text] [Related]
10. Mullerian inhibiting substance promotes interferon gamma-induced gene expression and apoptosis in breast cancer cells.
Hoshiya Y; Gupta V; Kawakubo H; Brachtel E; Carey JL; Sasur L; Scott A; Donahoe PK; Maheswaran S
J Biol Chem; 2003 Dec; 278(51):51703-12. PubMed ID: 14532292
[TBL] [Abstract][Full Text] [Related]
11. Mullerian inhibiting substance regulates androgen-induced gene expression and growth in prostate cancer cells through a nuclear factor-kappaB-dependent Smad-independent mechanism.
Tran TT; Segev DL; Gupta V; Kawakubo H; Yeo G; Donahoe PK; Maheswaran S
Mol Endocrinol; 2006 Oct; 20(10):2382-91. PubMed ID: 16740653
[TBL] [Abstract][Full Text] [Related]
12. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK
Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449
[TBL] [Abstract][Full Text] [Related]
13. Genetic studies of the AMH/MIS signaling pathway for Müllerian duct regression.
Jamin SP; Arango NA; Mishina Y; Hanks MC; Behringer RR
Mol Cell Endocrinol; 2003 Dec; 211(1-2):15-9. PubMed ID: 14656471
[TBL] [Abstract][Full Text] [Related]
14. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
15. AMH signaling: from receptor to target gene.
Visser JA
Mol Cell Endocrinol; 2003 Dec; 211(1-2):65-73. PubMed ID: 14656478
[TBL] [Abstract][Full Text] [Related]
16. Müllerian inhibiting substance inhibits branching morphogenesis and induces apoptosis in fetal rat lung.
Catlin EA; Tonnu VC; Ebb RG; Pacheco BA; Manganaro TF; Ezzell RM; Donahoe PK; Teixeira J
Endocrinology; 1997 Feb; 138(2):790-6. PubMed ID: 9003016
[TBL] [Abstract][Full Text] [Related]
17. Müllerian inhibitory substance induces growth of rat preantral ovarian follicles.
McGee EA; Smith R; Spears N; Nachtigal MW; Ingraham H; Hsueh AJ
Biol Reprod; 2001 Jan; 64(1):293-8. PubMed ID: 11133686
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of steroidogenesis in Leydig cells by Müllerian-inhibiting substance.
Fynn-Thompson E; Cheng H; Teixeira J
Mol Cell Endocrinol; 2003 Dec; 211(1-2):99-104. PubMed ID: 14656482
[TBL] [Abstract][Full Text] [Related]
19. Components of the anti-Müllerian hormone signaling pathway in gonads.
di Clemente N; Josso N; Gouédard L; Belville C
Mol Cell Endocrinol; 2003 Dec; 211(1-2):9-14. PubMed ID: 14656470
[TBL] [Abstract][Full Text] [Related]
20. YWK-II protein as a novel G(o)-coupled receptor for Müllerian inhibiting substance in cell survival.
Yin X; Ouyang S; Xu W; Zhang X; Fok KL; Wong HY; Zhang J; Qiu X; Miao S; Chan HC; Wang L
J Cell Sci; 2007 May; 120(Pt 9):1521-8. PubMed ID: 17452623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
